- 1 TITLE: Effects of a clinical decision support system and patient portal for preventing medication-
- 2 related falls in older fallers: Protocol of a cluster randomized controlled trial with embedded process
- 3 and economic evaluations (ADFICE_IT)
- 4

5 FULL NAMES AND INSTITUTIONAL ADDRESSES FOR ALL AUTHORS:

- 6 Kelly K. de Wildt* (2, 4)
- 7 Bob van de Loo* (2, 3, 4)
- 8 Annemiek J. Linn (1)
- 9 Stephanie K. Medlock (2, 5)
- **10** Sara S. Groos (1)
- 11 Kim J. Ploegmakers (2, 4)
- 12 Lotta J. Seppala (2, 4)
- 13 Judith E. Bosmans (6)
- 14 Ameen Abu-Hanna (2, 5)
- 15 Julia C.M. van Weert (1)
- 16 Natasja M. van Schoor (2, 3)
- 17 Nathalie van der Velde (2, 4)
- 18 on behalf of the ADFICE_IT study team
- 19 * Kelly de Wildt and Bob van de Loo are shared first co-authors
- 20 CORRESPONDING AUTHOR: n.vandervelde@amsterdamumc.nl
- 21

22 Affiliations

- 23 1 Amsterdam School of Communication Research, University of Amsterdam, Amsterdam, the
- 24 Netherlands
- 25 2 Amsterdam Public Health research institute, Amsterdam, The Netherlands.
- 26 3 Amsterdam UMC location Vrije Universiteit Amsterdam, Epidemiology and Data Science, De
- 27 Boelelaan 1117, Amsterdam, Netherlands.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

28 4 Amsterdam UMC location University of Amsterdam, Internal Medicine, Section of Geriatric

29 Medicine, Meibergdreef 9, Amsterdam, Netherlands.

30 5 Amsterdam UMC location University of Amsterdam, Department of Medical Informatics,

31 Meibergdreef 9, Amsterdam, Netherlands.

32 6 Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam

33 Public Health Research Institute, Van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands

34

35 **ABSTRACT**:

Background: Falls are the leading cause of injury-related mortality and hospitalization among adults

aged \geq 65 years. An important modifiable fall-risk factor is use of fall-risk increasing drugs (FRIDs).

38 However, deprescribing is not always attempted or performed successfully. The ADFICE_IT trial

evaluates the combined use of a clinical decision support system (CDSS) and a patient portal for

40 optimizing the deprescribing of FRIDs in older fallers. The intervention aims to optimize and enhance

shared decision making (SDM) and consequently prevent injurious falls and reduce healthcare-relatedcosts.

43 Methods: A multicenter, cluster-randomized controlled trial with process evaluation will be conducted 44 among hospitals in the Netherlands. We aim to include 856 individuals aged \geq 65 years that visit the falls clinic due to a fall. The intervention comprises the combined use of a CDSS and a patient portal. 45 46 The CDSS provides guideline-based advice with regard to deprescribing and an individual fall-risk 47 estimation, as calculated by an embedded prediction model. The patient portal provides educational 48 information and a summary of the patient's consultation. Hospitals in the control arm will provide care-as-usual. Fall-calendars will be used for measuring the time to first injurious fall (primary 49 50 outcome) and secondary fall outcomes during one year. Other measurements will be conducted at 51 baseline, 3, 6, and 12 months and include quality of life, cost-effectiveness, feasibility, and shared decision-making measures. Data will be analyzed according to the intention-to-treat principle. 52 53 Difference in time to injurious fall between the intervention and control group will be analyzed using 54 multilevel Cox regression.

55	Discussion: The findings of this study will add valuable insights about how digital health informatics
56	tools that target physicians and older adults can optimize deprescribing and support SDM. We expect
57	the CDSS and patient portal to aid in deprescribing of FRIDs, resulting in a reduction in falls and
58	related injuries.
59	Trial registration: ClinicalTrials.gov NCT05449470 (7-7-2022)
60	Keywords: fall prevention, fall-risk increasing drugs (FRIDs), older patients, outpatient clinic,
61	prediction model, Clinical decision support system, patient portal, Shared Decision Making (SDM),
62	randomized controlled trial (RCT), study protocol
63	Participant recruitment: 7 July 2022-ongoing *
64	* Results of this study have not yet been published or submitted to any journal.
65	Protocol version: 1
66	Trial sponsor: Amsterdam UMC, Meibergdreef 9, 1105 AZ Amsterdam
67	
68	Background
69	Falling among adults aged 65 years and older represents a serious public health problem.
70	Approximately 30% of adults aged 65 or older falls each year. Moreover, falls are the leading cause of
71	injury-related mortality and hospitalization, with one out of five falls resulting in severe injury (1). In
72	the Western European region, 8.4 million adults aged 70 and older sought medical attention due to a
73	fall-related injury, and 54 504 older adults died due to falls in 2017 alone (2). The incidence rate of
74	fall-related injuries increases substantially with age (2).
75	Besides physical injuries such as head wounds and fractures (3,4), falls can also lead to the
76	development of fear of falling (5,6), reduced perceived quality of life (7), reduced physical activity (8),
77	physical decline (9), social isolation (10), increased healthcare utilization, and institutionalization
78	(9,11,12). Furthermore, falls pose a substantial economic burden as fall-related costs are estimated to
79	amount to 0.85 to 1.5 percent of the total healthcare expenditures in Western countries (13).
80	Falls have a complex etiology and are associated with several risk factors, such as history of
81	falls (14), impaired mobility (14), frailty (15), chronic health conditions (16), fear of falling (17),
82	depression (18), cognitive impairment (19), increasing age (18), and female gender (18). In addition, a

large body of research has linked the use of certain medications to falls (20–22). Medications 83 84 recognized as fall-risk increasing drugs (FRIDs) include antipsychotics, antidepressants, diuretics, and 85 opioids (23). Studies have reported that 65 to 93 percent of older adults admitted with fall-related 86 injuries use at least one FRID (24). Antidepressants were the most commonly used FRID at the time of 87 the fall-related injury, with a prevalence between 15 and 40 percent (24). Despite the growing evidence on medication as an important modifiable risk factor, 88 89 deprescribing in older adults is often not attempted or performed unsuccessfully. Physicians generally 90 find deprescribing challenging since it requires complex decision-making in the context of polypharmacy and multi-morbidity (25). To be precise, physicians find it difficult to identify which 91 92 patients are at risk of a medication-related fall and it is not always clear which medications should be 93 considered for withdrawal and whether safer alternatives are available. Moreover, patients' beliefs 94 regarding their medication use may further hinder effective FRIDs deprescribing. Research indicates patients are generally not concerned about possible adverse effects from their regular medication and 95 96 not aware of medication management as an effective fall-prevention strategy (26.27). More effective 97 communication may help raise awareness and consequently prompt patients to adopt to and comply 98 with deprescribing as a treatment option. Moreover, communication is a two-way process and research 99 suggests that interventions targeting both physicians and patients may be more effective than 100 interventions that only target either one (28). Given these multifaceted complications, a 101 multicomponent intervention is expected to improve FRIDs deprescribing in older adults and thereby 102 help prevent medication-related falls. 103 There is growing attention for the role of SDM in deprescribing (29-31). SDM can be defined as an approach where clinicians and patients share the best available evidence when making decisions. 104 105 In doing so, patients are supported to consider options and to achieve informed preferences (32). In

106 complex patient cases with multiple treatment options, as is often the case in deprescribing in older

adults, SDM has been found to lead to more informed decision-making, better participation in

108 decision-making, more self-efficacy, increased knowledge, and reduced decisional conflict of patients

in disadvantaged groups, such as older patients (33–35). Therefore, it is expected that enhanced SDM

110 would support the FRIDs deprescribing process as well as improve patient compliance and adherence

to the new treatment plan. This, in turn, may lead to a decrease in medication-related falls among olderadults.

113 Clinical decision support systems (CDSS) may help physicians in the deprescribing process of 114 FRIDs and may stimulate SDM. A CDSS is a computerized system that aims to support clinicaldecision making by generating assessments or recommendations based on the characteristics of an 115 individual patient. CDSSs generate patient-specific output based on an existing knowledge base or 116 117 based on predictive modelling methods. CDSSs are increasingly used for improving adherence to 118 clinical guidelines as well as for preventing prescription errors and checking for drug interactions (36). Use of CDSSs in the prevention of falls has been studied in in- and outpatient settings (37–40). 119 However, these studies were all limited in scope as they focused on a select number of FRIDs, did not 120 use utilize predictive modelling methods for generating patient-specific output, or did not address risk 121 122 communication or shared decision-making (SDM) (37-40).

A tool that could stimulate patients to participate in SDM is a patient portal, which allows patients to access their clinical data through a secure website (41). A recent systematic literature review on the impact of patient portals on health outcomes found that patient portals can enhance preventive behaviors and adherence to therapy (42). Furthermore, a qualitative study revealed that patients thought that a portal would facilitate them in seeking medical advice in between visits (e.g., on medication side effects) and that this would stimulate patient-driven communication (43).

129 Given this backdrop, the ADFICE IT project (Alerting on adverse Drug reactions: Falls 130 prevention Improvement through developing a Computerized clinical support system: Effectiveness of 131 Individualized medicaTion withdrawal) was initiated to develop and evaluate a multicomponent intervention for optimizing FRIDs deprescribing and consequently improve patient outcomes. The 132 intervention comprises the combined use of a CDSS and a patient portal. The CDSS includes a 133 134 personalized fall risk prediction, which is used to estimate and visualizes a patient's fall risk. Furthermore, the CDSS gives insight in which of the patient's medications can contribute to this fall-135 136 risk, provides suggestions with safer medication alternatives, provides guideline-based medication 137 advice, and provides an overview of the possible treatment actions. The patient portal provides general 138 fall-related educational information (e.g. information about falls prevention, FRIDs, and FRIDs

Page 5 of 43

deprescribing) and information to help patients prepare for their visit to the falls clinic. After the falls 139 clinic visit, the patient portal will show a summary of the patient's treatment plan as discussed during 140 141 the consultation. These features of the CDSS and patient portal may help to optimize and enhance 142 (shared) decision making during the consultation. Consequently, it is expected that this will lead to less injurious falls among older adults and reduce healthcare-related costs. 143 The primary aim of the ADFICE IT cluster randomized controlled trial is to assess the 144 145 effectiveness of the multicomponent intervention, comprised of a CDSS and patient portal, compared 146 with usual care. Effectiveness will be assessed in terms of time to first injurious fall (primary 147 outcome). In addition, as secondary aims we will study the cost-effectiveness and feasibility of the intervention. 148 149 150 Methods The SPIRIT criteria were used as guideline for the reporting of this protocol paper (44) 151 152 (Supplementary File 1). The CONSORT 2010 Statement: extension to cluster randomised controlled *trials* will be used to further guide the reporting of the results of the trial (45). 153 The design and the development of the ADFICE IT intervention was guided by the Medical 154 Research Council (MRC) Framework for Complex Interventions (46). In the preparation phase of the 155 156 MRC framework, we developed a prediction model for estimating a patient's risk of falling (47). The 157 prediction model is currently being externally validated. In the development phase, we identified evidence and theory regarding CDSS and patient portal end users' preferences and needs, and 158 extended these with empirical research (i.e. survey (48)), interviews) to inform our decisions regarding 159 160 the design of the intervention. Furthermore, we incorporated guideline- and expert consensus-based medication advices (e.g. deprescribing advice or use of safer alternative medication) in the CDSS (23). 161 In the feasibility/piloting phase of the MRC framework, we tested the usability of the user interface of 162 our intervention through usability studies. The present paper describes the protocol for the final phase 163 164 of the project in which we will evaluate the effectiveness of the intervention. 165

166 Study design and settings

167	To evaluate the effectiveness of our multicomponent (CDSS and patient portal) intervention in
168	preventing injurious falls among older adults, a multicenter cluster-randomized controlled trial will be
169	conducted among new falls clinic patients of ten Dutch hospitals. These patients have been referred for
170	a multifactorial falls assessment to the geriatrics departments by their general practitioner, the
171	emergency department, or other specialists because of a history of falling or an increased risk of
172	falling.
173	
174	Ethical considerations
175	The ADFICE_IT study protocol was reviewed and approved by the Medical Ethics review board of
176	the Amsterdam University Medical Centres (METC AMC 2021_061). All study participants will
177	asked to sign an informed consent prior to data collection. The trial is registered with
178	ClinicalTrials.gov (DATE; 7-7-2022, identifier: NCT05449470).
179	
180	Eligibility criteria
181	The study population consists of older adults visiting a falls clinic. Falls clinics typically perform
182	detailed multidisciplinary fall risk assessments and make recommendations or implement a range of
183	targeted falls and falls injury-prevention strategies based on the assessment findings (49). Falls clinics
184	at Dutch hospitals that use Epic software (Epic Systems Corporation; Verona, Wisconsin, United
185	States) as their electronic patient record system were eligible to be included as a study center. Patients
186	meeting the following criteria are eligible for inclusion:
187	- Aged 65 years and older;
188	- History of at least one fall in the past year;
189	- A Mini-Mental State Examination (MMSE) score of 21 points or higher or equivalently a
190	Montreal Cognitive Assessment (MOCA) Dutch score of 16 points or higher (50);
191	- Use of at least one FRID (as defined by the Dutch Federation of Medical Specialists (51));
192	- Sufficient command of the Dutch language in speech and writing; and
193	- Willingness to sign informed consent.
194	

195	Potential subjects will be excluded if they:
196	- Already participate in another (intervention) study;
197	- Have a life expectancy of less than one year; or
198	- Suffer from severe mobility impairment (i.e. bedridden, e.g. inability to walk short distances
199	with assistance of a walking aid).
200	
201	Participant recruitment has started in July 2022 and is ongoing.
202	
203	Randomization and blinding
204	Since the intervention needs to be integrated into the physician's workflow, randomization will be
205	performed at hospital level prior to the start of inclusion. We evaluated use of the CDSS in usability
206	studies among physicians of one of the locations of the Amsterdam UMC, i.e. location AMC. To avoid
207	possible contamination of the intervention, the Amsterdam UMC: location AMC will be exempted
208	from randomization and included in the intervention group by default. To assure the control and
209	intervention hospitals remain similar with respect to their patient population, the other location of
210	Amsterdam UMC, i.e. location VUmc, will be included in the control group by default.
211	Randomization of the remaining hospitals will be done based on a 1:1 allocation ratio and stratified
212	based on whether the hospital is academic or non-academic. The randomization procedure will be
213	done by an independent statistician using computer-generated random numbers. Blinding of the
214	intervention allocation is not possible since both physicians and patients will have to interact with the
215	CDSS and patient portal. Researchers will be blinded to group allocation during the statistical
216	analyses.
217	

218 Intervention

219 The multicomponent intervention comprises the combined use of a CDSS and a patient portal.

220 Furthermore, patients in the intervention arm will receive a Question Prompt List (QPL) prior to their

consultation. Physicians in the intervention arm will be trained to work with the CDSS. The control

hospitals will only receive a general overview of the study, including the procedures. Patients in thecontrol arm will receive care-as-usual.

224

225 *CDSS*

226 Relevant FRIDs were identified based on the Dutch fall guideline (51) and STOPPFall (Screening

227 Tool of Older Persons Prescriptions in older adults with high fall risk) tool (23). These two sources

form the foundation for the CDSS' clinical knowledge base. For each class of identified FRIDs,

relevant recommendations about deprescribing from more than 30 different Dutch clinical guidelines

have been extracted and formalized using the Logical Elements Rule Method (52). Thus, the CDSS

provides point-of-care guideline and expert consensus based medication withdrawal advice (23) as

well as a personalized fall-risk estimation based on a prediction model (47).

233 The CDSS will be integrated in the electronic patient record system and workflow of physicians. On the CDSS start page, the physician can check the data that was pulled from the 234 235 electronic patient record system, and see the patient's estimated risk of falling. On the next screen, the 236 physician can see the advice of the CDSS for each of the patient's prescribed current medications. 237 Based on the given advice, the physician can decide to propose a change in treatment for a specific 238 medication. The physician can discuss those proposed treatment changes with the patient using the consultation screen. The final screen will allow the physician to copy-paste all treatment decisions to 239 240 the patient's electronic health record, print a patient-friendly summary of the individual treatment plan, 241 and send it to the patient portal.

242

243 *Patient portal*

Patients in the intervention arm will receive access to the patient portal prior to their visit to the falls clinic. At that time, the patient portal provides general fall-related educational information (e.g. information about falls prevention, FRIDs, and FRIDs deprescribing) and information to help patients prepare for the falls clinic visit. After their consultation with the physician during their fall clinic visit, the patients will also receive access to the additional patient portal pages with the personalized fall-risk estimate and the treatment plan as discussed with the physician.

2	с	n
Ζ	Э	υ

251 *Question Prompt List (QPL)*

252	Patients in the intervention arm will receive a printed QPL prior to their visit to the falls clinic. A QPL
253	is a structured list of questions designed to encourage information gathering, which patients can use as
254	example questions to ask during the consultation (53). A QPL stimulates agenda setting and helps
255	patients to remember important questions. In other contexts (e.g. oncology), QPLs have been found to
256	improve communication and stimulate participation in older patients (53). Our QPL will consist of
257	preparatory questions and concerns that need to be completed by the patient preceding the consultation
258	(e.g. 'Which of the medications that I am currently taking are truly crucial for my health?'). Patients
259	will be asked to bring it with them to consultation.
260	
261	Training

Physicians will be trained in small groups (i.e., the geriatric staff of a specific intervention hospital) on how to use the system during a one-hour training session. The training addresses four components: 1) general overview of the study and its aim, 2) (issues in) FRIDs deprescribing, 3) employing SDM and the QPL during a consultation, and 4) practical instructions on how to use the CDSS. AD*F*ICE_IT project team members (i.e., an experienced geriatrician and two communication scholars) will provide the training. Afterwards, an online version of the training will be available to the physicians.

268

269 Comparator

270 Patients treated at the control hospitals will receive care-as-usual, e.g. a multifactorial fall assessment

at a falls clinic. Usually such an assessment takes up around 3-4 hours, distributed over 1 or 2 days,

and is concluded by a consultation between the patient and the physician.

273

274 **Procedures**

Patients who schedule an appointment at any of the participating falls clinics (i.e., intervention and
control hospitals) will receive a letter containing information on the objectives and procedures of the

study and an invitation to participate. For patients in the intervention arm, the invitation letter will alsoinclude a printed QPL and a link to the patient portal.

279 At the falls clinic, eligibility will be determined according to the in- and exclusion criteria by 280 the hospitals' staff members. The researcher will then provide oral and written information about the 281 study to eligible patients. Patients who are interested in participating in the study will be asked to sign an informed consent form. Next, the falls clinic assessments will be carried out as usual. In the 282 283 intervention group, the physician will use the CDSS prior to the consultation to understand a patient's 284 fall risk and medical background as well as during the consultation with the patient. Consultations in the control group are carried out according to care as usual. After the consultation, the research 285 286 assistants will ask the included patients and their caregivers (if applicable) to fill out a set of questionnaires (see "Data Collection"). After the visit to the falls clinic, patients in the intervention 287 288 group will be able to review information about their consultation with the physician (i.e., their 289 treatment plan) and their estimated fall risk in the patient portal.

290

291 Data collection

We will collect a wide range of quantitative and qualitative data to assess the effectiveness and costeffectiveness and to evaluate the implementation of the intervention (see Figure 1 for complete overview of measurements). Questionnaires will be administered at baseline and 3, 6, and 12 months after baseline (Figure 1).

296

297 Estimating the effectiveness of the intervention on trial outcomes

The primary outcome is time to first injurious fall. An injurious fall is defined as a fall resulting in
wounds, bruises, sprains, cuts, medically recorded fractures, head or internal injury, requiring
medical/health professional examination, accident and emergency treatment, or inpatient treatment
(54). This definition is consistent with moderate and serious injuries, as proposed by Schwenk (2012).
Secondary outcomes include number of injurious falls, total number of falls, time to first fall resulting
in any injuries (i.e., fall that results in minor, moderate, or severe injuries), total number of falls
resulting in any injuries, time to first fall and (health-related) quality of life. Falls are defined as an

Page 11 of 43

305 unexpected event in which the participants come to rest on the ground, floor, or lower level (55). At baseline, patients in both groups receive a falls calendar to keep track of falls, fall-related injuries, and 306 fall-related healthcare use on a weekly basis for 12 months. The falls calendars will be returned every 307 308 month by mail. Incomplete, missing or unclear data will be further inquired by telephone. Healthrelated) quality of life is assessed using the EuroQol-5D-5L (EQ-5D-5L) index value, EQ-5D visual 309 310 analogue scale and the Older Persons and Informal Caregivers Survey Short Form (TOPICS-SF) 311 summary score (56,57). EQ-5D-5L is a standardized instrument for measuring health-related quality of 312 life (58). The health states based on the five EQ-5D-5L domains will be converted to utility scores 313 using the Dutch EQ-5D-5L tariff (56). The TOPICS-SF is a 22-item questionnaire for measuring health-related quality of life, which was developed to evaluate patient-reported outcomes in the 314 context of multidimensional geriatric care (57). 315 316 317 Estimating the cost-effectiveness of the intervention 318 Societal costs related to the intervention and care as usual will be assessed using the institute for 319 Medical Technology Assessment Medical Consumption Questionnaire (iMCQ) (59) and the institute 320 for Medical Technology Assessment Productivity Cost Questionnaire (iPCO; Figure 1) (60). The 321 iMCQ is a non-disease specific questionnaire for measuring health care use (59). The iPCQ is a questionnaire for measuring productivity losses of paid work due to absenteeism, presenteeism and 322 323 productivity losses related to unpaid work (60). Costs will be calculated by multiplying the volumes of 324 healthcare use with the corresponding unit prices. Lost productivity costs will be calculated using the 325 friction cost approach.

326

327 Process evaluation

The process evaluation will consist of two parts: a) assessing the feasibility of the intervention and b)evaluating how the intervention facilitates SDM.

330

331 Process evaluation: Feasibility

To assess the feasibility of the intervention, we will collect the following: 1) data logged by the CDSS and patient portal, 2) participation data of the CDSS training, 3) physician satisfaction regarding the CDSS, 4) the Technology Acceptance Model (TAM; (61)) questionnaire; 5) the Website Satisfaction Scale questionnaire (WSS (62)), 6) videotaped consultations, 7) pharmacy records, and 8) falls calendar entries.

Usage data of the CDSS and patient portal will be measured throughout the study period. The 337 338 extent to which the intervention was implemented as intended (fidelity/dose delivered) and the extent 339 to which the participants actively engage with the intervention (dose received/exposure) will be 340 assessed through data logged by the CDSS and patient portal, and the videotaped consultations. Dose 341 received/exposure will also be assessed through participation data of the CDSS training. Reach/participation rate will be assessed through data logged by the CDSS to analyze the extent to 342 343 which physicians propose changes in FRID prescriptions. Patients will be asked to self-report changes in medication use on the fall calendar on a weekly basis. These falls calendar entries and pharmacy 344 records will be used to analyze the extent to which patients adhere to the physicians' advice and 345 346 changes in the treatment plan. Satisfaction with the intervention (dose received/exposure) will be 347 measured through physician evaluations of the CDSS and the WSS questionnaire (patients). The TAM questionnaire assesses the perceived usefulness, perceived ease of use, and intended usage of the 348 CDSS, and the WSS measures the comprehensibility, satisfaction and Emotional Support of the 349 350 patient portal (62). Finally, barriers and facilitators (context) will be assessed through the videotaped 351 consultations, and physician evaluations of the CDSS by means of a survey.

352

353 Process evaluation: Shared Decision Making

SDM will be measured through self-reported questionnaires in the full sample (i.e. perceived SDM; the iSHAREpatient and iSHAREphysician (63). In addition, we aim to measure observed SDM in a subsample (n=50) through videos of consultations (i.e. the Observer OPTION^{MCC} Multiple Chronic Conditions coding scheme (64)). SDM will be assessed in relation to two affective-cognitive outcomes: preparation for decision-making through the Preparation for Decision-making scale (PrepDM; (65)) and decisional conflict through the Decisional Conflict Scale (DCS; low literacy

Page 13 of 43

version; (66)). The 'Question Format DCS – 10 item 3 response categories' version of the DCS is 360 recommended to be used for low literacy groups (67). In addition, recall of information will be 361 362 assessed in the subsample through the Netherlands Patient Information Recall Questionnaire (NPIRQ; 363 (68)). The iSHARE questionnaire will be used to measure perceived SDM from both the patient and physician perspective. The NPIRQ consists of multiple-choice questions, completion items, and open-364 ended questions related to information about treatment and recommendations on how to handle side 365 366 effects (68). Patient responses on the questionnaire will be checked against the actual communication 367 in video recordings of the consultations. In addition, the PrepDM will be used to assess how patients 368 evaluate the usefulness of the patient portal and QPL for preparing themselves for communicating with their physician during the consultation. Finally, we will code observed shared (triadic) decision-369 370 making between the physician, the patient, and if relevant, the informal caregiver, in the videotaped consultations by using the Observer OPTION^{MCC} Multiple Chronic Conditions coding scheme (64). 371

SDM will be assessed using questionnaires in the full sample and video observations in a 372 373 subsample. The subsample of 50 consultations in both intervention and control group will be video 374 recorded to assess the level of SDM. After working with the CDSS for a couple of months, 375 intervention-group physicians will be asked to fill out an online questionnaire about their satisfaction 376 with the CDSS, to indicate whether they thought the advice provided by the CDSS was (sufficiently) accurate, if they perceived any barriers in using the CDSS system, and if they thought the patient 377 378 perceived barriers in using the patient portal. Pharmacy records will be used to make an inventory of 379 the prescribed medicines for individual patients at baseline and 12 months after baseline to assess 380 adherence.

381

382 Data management

Data will be handled confidentially and only a limited number of members of the study team will have access to the complete datasets. The collected and pseudonymized questionnaire data for each local center will be transferred to the Amsterdam UMC, where it will be entered, stored and processed in Castor. In addition, the digital CDSS and patient portal data will be stored locally at each hospital. Every 3-6 months, study data will be extracted to .csy text files and stored in a secured folder.

Page 14 of 43

388	Furthermore, administrative data will be stored in a secured SQL database. Finally, data from both
389	control and intervention patients will be extracted from Epic every 3-6 months to .csv text files (e.g.
390	medication data, problem lists, relevant lab values, and the prediction model variables). Data from
391	individual patients will be pseudonymized, and the different datasets can only be linked through a
392	participant identification number, which is stored in a separate data system. These data management
393	systems all comply in accordance with the European Union General Data Protection Regulation.
394	
395	Statistical analysis
396	Data of the RCT will be analyzed according to the intention-to-treat principle. P-values of < 0.05 will
397	be considered statistically significant.
398	
399	Estimating the effectiveness of the intervention on trial outcomes
400	For every participant, we will assess fall incidents during a fixed follow-up period of 12 months,
401	which will start after a set 1 month, during which the dose of FRIDs will be stopped or decreased.
402	Difference in time to injurious fall between the intervention and control group in the follow-up period
403	will be analyzed by means of a multilevel Cox regression model based on hospital level (69). Model
404	fit will be assessed using standard approaches (e.g., the proportional hazards assumption with
405	Schoenfeld residuals). We will adjust all models for age, sex and type of hospital, i.e. academic versus
406	non-academic. In a sensitivity analysis, we will additionally adjust for significant baseline differences.
407	Difference in total number of (injurious) falls in the follow-up period between the control and
408	intervention groups will be analyzed by means of multilevel Poisson regression models based on
409	hospital level. In the case of overdispersion, we will apply either quasi-Poisson regression or negative
410	binomial regression depending on the observed distribution of the data. Difference between the
411	intervention and control group with respect to time to any fall and time to fall that results in any
412	injuries will be analyzed by means of survival analyses, similarly to the primary outcome.
413	Differences in EQ-5D-5L index score, EQ-5D visual analogue scale, and TOPICS-SF
414	summary score between the intervention and control group after 12 months will be analyzed by means
415	of linear mixed models. These models will be adjusted for the baseline value of the outcome (70).

416	
417	Estimating the cost-effectiveness of the intervention
418	Differences in costs and effects between intervention and usual care will be estimated using seemingly
419	unrelated regression to retain the correlation between costs and effects. Incremental cost-effectiveness
420	ratios will be calculated by dividing the difference in costs between CDSS and usual care due to
421	differences in incidence in injurious falls as well as gained quality-adjusted life years (QALYs).
422	Bootstrapping techniques will be used to estimate the uncertainty surrounding the incremental cost-
423	effectiveness ratios. Uncertainty will be shown in cost-effectiveness planes and cost-effectiveness
424	acceptability curves.
425	
426	Process evaluation: Feasibility
427	In the first part of the process evaluation we will evaluate the feasibility of the intervention, and
428	describe 1) user data, 2) participation in and evaluation of the training, 3) physician and patient
429	satisfaction and acceptance of the CDSS and patient portal. These descriptive statistics will be
430	presented as percentages or means with standard deviations.
431	
432	Process evaluation: Shared Decision Making
433	Differences in mean change between arms will be analyzed with the use of multi-level modelling and
434	will be expressed as mean differences with 95% CIs. We will analyze differences in perceived SDM
435	and observed SDM for both patients and physicians in the intervention and control groups. Finally, we
436	will assess the differences between the intervention and control groups on recall (NPIRQ), adherence
437	(pharmacy records), and quality of life (EQ-5D-5L).
438	
439	Per protocol analysis
440	Logged data by the CDSS and patient portal will be used to select participants for a per protocol
441	analysis for the primary outcome. In this analysis, we will only include patients from the experimental

group that meet the following two criteria 1) physicians used the CDSS in the consult with the patients

and 2) physician used the 'print' button in the CDSS or the patient visited the patient portal at leastonce after the consultation.

- 445
- 446 Sample size
- 447 Sample sizes of n = 385 in the intervention and n = 385 in the control group (10 clusters with 77
- 448 patients in each cluster) are needed to detect a difference in proportion of injurious falls of 0.10 with
- 449 80% power. We inferred the proportion of patients who will experience an injurious fall to be 0.22 in
- 450 the control and 0.12 in the intervention group. In these calculations, we assumed the two-sided
- 451 significance level of 5% and an intraclass correlation coefficient of 0.01 to account for clustering (71).
- 452 Presupposing a drop-out rate of 10%, 856 patients will need to be included.
- 453

454 Monitoring

- A data monitoring committee will not be established since the overall risk associated with the trial isconsidered negligible.
- 457

458 Harms

- All adverse events and serious adverse events reported by the subject or observed by the researchers or
 his staff will be recorded in an electronic database. Serious adverse events will also be reported to the
 medical ethics committee of the Amsterdam UMC.
- 462

463 **Discussion**

- 464 The multicenter RCT described in this paper will assess: a) the effectiveness of the multicomponent
- intervention (i.e., use of CDSS and patient portal) compared with usual care. Effectiveness will be
- 466 assessed in terms of time to first injurious fall (primary outcome). As secondary aims, cost-
- 467 effectiveness and the feasibility of the intervention will be assessed.
- 468 The deprescribing of FRIDs requires complex decision making. We expect that the
- 469 implementation of our CDSS and patient portal, supported by a prediction model and guideline-based

advice, will aid in optimizing deprescribing decisions for both the physician and patient, consequently
reducing fall risk. In line with the expectation that the intervention will aid in the prevention of
injurious falls, it is hypothesized that the intervention will be more cost-effective compared to care-asusual regarding fall-related health care costs. The direct healthcare and follow-up care resulting from
injurious falls among older adults potentially involve 0.85 to 1.5 percent of the total healthcare
expenditures in Western countries (13).

476 The process evaluation will evaluate a) the implementation of the intervention and b) how this 477 intervention leads to enhanced SDM and patient outcomes. A systematic review has suggested that 478 SDM can lead to better affective-cognitive outcomes, e.g. improved satisfaction and less decisional conflict (72). Thus, we hypothesize that physicians and geriatric patients as well as their caregivers 479 480 will evaluate the intervention workflow more positively compared to the care-as-usual workflow and will engage in more SDM regarding the patient's treatment plan. Recent studies have illustrated that 481 482 compliance to FRID-deprescribing is often poor. In a study by Boyé et al. (73), researchers found that 483 compliance to their intervention of FRIDs-withdrawal was limited among patients. The researchers 484 found that 35 percent of all deprescribing attempts were unsuccessful, either due to non-compliance, 485 recurrence of the initial indication for prescribing, or additional medication being described for newly diagnosed conditions. Moreover, the STRIDE trial, a multicenter randomized controlled trial by Basin 486 et al. (74) evaluated a multifactorial intervention that included the use of motivational interviewing to 487 488 encourage patients to choose recommendations they were willing to address. Among the patients for 489 which medication use was identified as a risk factor, only 29 percent of patients agreed to address this 490 risk. We expect that a higher degree of SDM will lead to more recall and knowledge among patients, leading to more treatment and medication adherence among patients. This in turn, could also lead to 491 492 less medication-related injurious falls among patients.

An important strength of our study is that we developed the intervention following the MRC
guidelines. The aim of the framework is to ensure that feasible interventions are empirically and
theoretically founded and that considerations are given both to the effectiveness of the intervention
and how it works. The intervention's end-users are included in each phase of the project. This way, we

will be able to optimally personalize the intervention's design to the heterogeneous needs of the end-users.

499 Another asset of our study is that it includes both an effect evaluation and a process 500 evaluation. This will help us to not only assess whether the intervention was effective, but the process 501 evaluation will also make it possible to assess whether the intervention was implemented correctly, and which implementation factors were facilitating or impeding. Gaining more insight into the context 502 503 will deepen our understanding of why the intervention was (not) successful. 504 The findings of this study will add valuable insights about how digital health informatics tools, 505 based on prediction models, can support SDM between physicians and older adults. This new 506 knowledge will be especially insightful in the case of FRIDs withdrawal among older adults. 507 Furthermore, this study will also contribute to the literature on risk communication, since it 508 investigates how physicians will use a visualized fall-risk estimate in their consultations with the 509 patient.

510

511 Outlook

If the ADFICE IT intervention will prove to be effective, it could be implemented in routine 512 healthcare practices. The hospitals in the intervention group can continue using the CDSS and patient 513 portal as they have done during the RCT, as the intervention will already be implemented in their 514 electronic patient record systems. The hospitals in the control group could also implement the CDSS 515 516 and patient portal software at the end of the study. Furthermore, the software will be available as open source to facilitate national and international implementation. We expect that once implemented at the 517 falls clinic of the geriatric departments, the ADFICE IT intervention will contribute to individualized 518 519 and cost-effective prevention of (medication-related) injurious falls among older adults.

520

521 Abbreviations

ADFICE_IT: Alerting on adverse Drug reactions: Falls prevention Improvement through developing a
 Computerized clinical support system: Effectiveness of Individualized medicaTion withdrawal;

524	CDSS: Clinical decision	support system; (CI: confidence interval:	DCS: Decisional	Conflict Scale; EQ-

- 525 5D-5L: EuroQol-5D-5L; FRID: Fall-Risk Increasing Drug; IMCQ: institute for Medical Technology
- 526 Assessment Productivity Cost Questionnaire Medical Consumption Questionnaire; IPCQ: institute for
- 527 Medical Technology Assessment Productivity Cost Questionnaire Productivity Cost Questionnaire;
- 528 MMSE: Mini-Mental State Examination; MOCA: Montreal Cognitive Assessment; MRC: Medical
- 529 Research Council; NPIRQ: Netherlands Patient Information Recall Questionnaire; PrepDM:
- 530 Preparation for Decision-making scale; QALY: quality-adjusted life years QPL: Question Prompt List;
- 531 RCT: Randomized Controlled Trial; SDM: Shared Decision Making; TAM: Technology Acceptance
- 532 Model; TOPICS-SF: The Older Persons and Informal Caregivers Survey Short Form; UI: User
- 533 Interface; WSS: Website Satisfaction Scale
- 534

535 **Dissemination policy**

- 536 The results of the ADFICE_IT study will be published in international, peer-reviewed, scientific
- 537 journals. In addition, results will be presented at (inter)national scientific conferences, seminars, public
- 538 events, and on the project website.
- 539
- 540 **Consent for publication**
- 541 Not applicable.
- 542
- 543 Availability of data and materials

All project data will be stored in accordance with General Data Protection Regulation. Data from the

trial will be made available for other researchers after the study is completed for replication purposes

- and for original research questions. To obtain data, researchers will need to submit an analysis
- 547 proposal, which will be evaluated by the ADFICE_IT Steering Group. More information on the
- 548 ADFICE_IT study can be found at http://www.onderzoeknaarvallen.nl (website information is also
- 549 available in English).
- 550

551 **Competing interests**

552	The authors	declare	that they	have no	competing	interests.
-----	-------------	---------	-----------	---------	-----------	------------

5	5	3
-	-	-

554 Funding

- 555 The ADFICE_IT study is supported by funding from the Netherlands Organization for Health
- 556 Research and Development (ZonMw, Grant 848017004), The Hague and the Amsterdams
- 557 Universiteitsfonds: Gepersonaliseerde Medicatieaanpassing bij Oudere Vallers. The study protocol
- 558 was reviewed by ZonMW.

559

560 Authors' contributions

- 561 NvdV, NMvS, AA-H, SM, JCMvW contributed in the conception of the study. All authors have made
- substantial contributions to the design of the study. BvdL and KKdW wrote the manuscript. All the
- authors read the draft, made contributions and approved the final manuscript.
- 564
- 565 Acknowledgements
- 566 Not applicable
- 567
- 568 Authors' information (optional)
- 569 Not applicable

570

571 **References**

- 572 1. Bergen G, Stevens MR, Burns ER. Falls and Fall Injuries Among Adults Aged ≥65 Years —
- 573 United States, 2014. MMWR Morb Mortal Wkly Rep. 2016;65:993–8. Available from:
- 574 http://dx.doi.org/10.15585/mmwr.mm6537a2
- 575 2. Haagsma JA, Olij BF, Majdan M, van Beeck EF, Vos T, Castle CD, et al. Falls in older aged
- adults in 22 European countries: incidence, mortality and burden of disease from 1990 to 2017.
- 577 Inj Prev. 2020 Oct;26(Supp 1):i67–74. Available from:
- 578 https://injuryprevention.bmj.com/lookup/doi/10.1136/injuryprev-2019-043347

- 579 3. Alexander BH, Rivara FP, Wolf ME. The cost and frequency of hospitalization for fall-related
- 580 injuries in older adults. Am J Public Health. 1992 Jul;82(7):1020–3. Available from:
- 581 https://pubmed.ncbi.nlm.nih.gov/1609903
- 582 4. Centers for Disease Control and Prevention. Home and Recreational Safety Important Facts
- about Falls [Internet]. 2017 [cited 2020 Apr 15]. p. 10–2. Available from:
- 584 https://www.cdc.gov/homeandrecreationalsafety/falls/adultfalls.html
- 585 5. Jung D. Fear of Falling in Older Adults: Comprehensive Review. Asian Nurs Res (Korean Soc
 586 Nurs Sci). 2008;2(4):214–22. Available from:
- 587 https://www.sciencedirect.com/science/article/pii/S1976131709600037
- 588 6. Peeters G, Bennett M, Donoghue OA, Kennelly S, Kenny RA. Understanding the aetiology of
- 589 fear of falling from the perspective of a fear-avoidance model A narrative review. Clin
- 590 Psychol Rev. 2020;79(October 2019):101862. Available from:
- 591 https://doi.org/10.1016/j.cpr.2020.101862
- 592 7. Hartholt KA, Van Beeck EF, Polinder S, Van Der Velde N, Van Lieshout EMM, Panneman
- 593 MJM, et al. Societal consequences of falls in the older population: Injuries, healthcare costs,
- and long-term reduced quality of life. J Trauma Inj Infect Crit Care. 2011;71(3):748–53.
- 595 8. Jefferis BJ, Iliffe S, Kendrick D, Kerse N, Trost S, Lennon LT, et al. How are falls and fear of
- falling associated with objectively measured physical activity in a cohort of community-
- 597 dwelling older men? BMC Geriatr. 2014;14(1):114. Available from:
- 598 https://doi.org/10.1186/1471-2318-14-114
- 599 9. Tinetti ME, Williams CS. The Effect of Falls and Fall Injuries on Functioning in Community-
- 600 Dwelling Older Persons. Journals Gerontol Ser A Biol Sci Med Sci. 1998 Mar
- 601 1;53A(2):M112–9. Available from: https://academic.oup.com/biomedgerontology/article-
- 602 lookup/doi/10.1093/gerona/53A.2.M112
- 603 10. Petersen N, König HH, Hajek A. The link between falls, social isolation and loneliness: A

604 sy	stematic review.	Arch Gerontol	Geriatr. 2020 Ma	y;88:104020.	Available from:
--------	------------------	---------------	------------------	--------------	-----------------

- 605 https://www.sciencedirect.com/science/article/pii/S0167494320300145
- 606 11. Stel VS, Smit JH, Pluijm SMF, Lips P. Consequences of falling in older men and women and
- risk factors for health service use and functional decline. Age Ageing. 2004 Jan 1;33(1):58–65.
- 608 Available from: https://academic.oup.com/ageing/article-lookup/doi/10.1093/ageing/afh028
- 12. Tinetti ME, Williams CS. Falls, Injuries Due to Falls, and the Risk of Admission to a Nursing
- 610 Home. N Engl J Med. 1997 Oct 30;337(18):1279–84. Available from:
- 611 http://www.nejm.org/doi/abs/10.1056/NEJM199710303371806
- 612 13. Heinrich S, Rapp K, Rissmann U, Becker C, König HH. Cost of falls in old age: a systematic
- 613 review. Osteoporos Int. 2010 Jun 19;21(6):891–902. Available from:
- 614 http://link.springer.com/10.1007/s00198-009-1100-1
- 615 14. Deandrea S, Lucenteforte E, Bravi F, Foschi R, La Vecchia C, Negri E. Risk Factors for Falls
 616 in Community-dwelling Older People. Epidemiology. 2010 Sep;21(5):658–68. Available from:
 617 https://journals.lww.com/00001648-201009000-00020
- 618 15. Cheng MH, Chang SF. Frailty as a Risk Factor for Falls Among Community Dwelling People:
- Evidence From a Meta-Analysis. J Nurs Scholarsh. 2017 Sep;49(5):529–36. Available from:
- 620 https://onlinelibrary.wiley.com/doi/10.1111/jnu.12322
- 621 16. Paliwal Y, Slattum PW, Ratliff SM. Chronic Health Conditions as a Risk Factor for Falls
- among the Community-Dwelling US Older Adults: A Zero-Inflated Regression Modeling
- 623 Approach. Biomed Res Int. 2017;2017:1–9. Available from:
- 624 https://www.hindawi.com/journals/bmri/2017/5146378/
- 625 17. Hadjistavropoulos T, Delbaere K, Fitzgerald TD. Reconceptualizing the Role of Fear of Falling
- and Balance Confidence in Fall Risk. J Aging Health. 2011 Feb 17;23(1):3–23. Available from:

627 http://journals.sagepub.com/doi/10.1177/0898264310378039

628 18. Ambrose AF, Paul G, Hausdorff JM. Risk factors for falls among older adults: A review of the

- 629 literature. Maturitas. 2013 May;75(1):51–61. Available from:
- 630 http://dx.doi.org/10.1016/j.maturitas.2013.02.009
- 631 19. Muir SW, Gopaul K, Montero Odasso MM. The role of cognitive impairment in fall risk
- among older adults: a systematic review and meta-analysis. Age Ageing. 2012 May;41(3):299–
- 633 308. Available from: https://academic.oup.com/ageing/article-
- 634 lookup/doi/10.1093/ageing/afs012
- 635 20. de Vries M, Seppala LJ, Daams JG, van de Glind EMM, Masud T, van der Velde N, et al. Fall-
- 636 Risk-Increasing Drugs: A Systematic Review and Meta-Analysis: I. Cardiovascular Drugs. J
- 637 Am Med Dir Assoc. 2018 Apr 1;19(4):371.e1-371.e9. Available from:
- 638 https://linkinghub.elsevier.com/retrieve/pii/S1525861017306989
- 639 21. Seppala LJ, Wermelink AMAT, de Vries M, Ploegmakers KJ, van de Glind EMM, Daams JG,
- 640 et al. Fall-Risk-Increasing Drugs: A Systematic Review and Meta-Analysis: II. Psychotropics. J
- 641 Am Med Dir Assoc. 2018 Apr 1;19(4):371.e11-371.e17. Available from:
- 642 https://linkinghub.elsevier.com/retrieve/pii/S1525861017307843
- 643 22. Seppala LJ, van de Glind EMM, Daams JG, Ploegmakers KJ, de Vries M, Wermelink AMAT,
- et al. Fall-Risk-Increasing Drugs: A Systematic Review and Meta-analysis: III. Others. J Am
 Med Dir Assoc. 2018 Apr 1;19(4):372.e1-372.e8.
- 646 23. Seppala LJ, Petrovic M, Ryg J, Bahat G, Topinkova E, Szczerbińska K, et al. STOPPFall
- 647 (Screening Tool of Older Persons Prescriptions in older adults with high fall risk): a Delphi
- study by the EuGMS Task and Finish Group on Fall-Risk-Increasing Drugs. Age Ageing. 2021
- 649 Jun 28;50(4):1189–99. Available from:
- 650 https://academic.oup.com/ageing/article/50/4/1189/6043386
- 651 24. Hart LA, Phelan EA, Yi JY, Marcum ZA, Gray SL. Use of Fall Risk-Increasing Drugs Around
- a Fall-Related Injury in Older Adults: A Systematic Review. J Am Geriatr Soc. 2020 Jun
- 653 17;68(6):1334–43. Available from: https://onlinelibrary.wiley.com/doi/10.1111/jgs.16369

654	25.	Tinetti ME,	Gordon C, Se	ogolow E,	Lapin P,	Bradley	EH.	Fall-Risk	Evaluation	and
-----	-----	-------------	--------------	-----------	----------	---------	-----	-----------	------------	-----

- 655 Management: Challenges in Adopting Geriatric Care Practices. Gerontologist. 2006 Dec
- 656 1;46(6):717–25. Available from: https://academic.oup.com/gerontologist/article-
- 657 lookup/doi/10.1093/geront/46.6.717
- 658 26. Bagge M, Tordoff J, Norris P, Heydon S. Older people's attitudes towards their regular
- 659 medicines. J Prim Health Care. 2013;5(3):234. Available from:
- 660 http://www.publish.csiro.au/?paper=HC13234
- 661 27. Laing SS, Silver IF, York S, Phelan EA. Fall Prevention Knowledge, Attitude, and Practices of
- 662 Community Stakeholders and Older Adults. J Aging Res. 2011;2011(2):1–9. Available from:
- 663 http://www.hindawi.com/journals/jar/2011/395357/
- 28. Légaré F, Ratté S, Stacey D, Kryworuchko J, Gravel K, Graham ID, et al. Interventions for
- 665 improving the adoption of shared decision making by healthcare professionals. In: Légaré F,
- editor. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd;
- 667 2010. Available from: https://doi.org//10.1002/14651858.CD006732.pub2
- 668 29. Jansen J, Naganathan V, Carter SM, McLachlan AJ, Nickel B, Irwig L, et al. Too much
- 669 medicine in older people? Deprescribing through shared decision making. BMJ. 2016 Jun
- 670 3;353(June):i2893. Available from: https://www.bmj.com/lookup/doi/10.1136/bmj.i2893
- 30. Weir K, Nickel B, Naganathan V, Bonner C, McCaffery K, Carter SM, et al. Decision-Making
- 672 Preferences and Deprescribing: Perspectives of Older Adults and Companions About Their
- 673 Medicines. Journals Gerontol Ser B. 2018 Sep 20;73(7):e98–107. Available from:
- https://academic.oup.com/psychsocgerontology/article/73/7/e98/4668532
- Thompson W, Reeve E, Moriarty F, Maclure M, Turner J, Steinman MA, et al. Deprescribing:
 Future directions for research. Res Soc Adm Pharm. 2019 Jun;15(6):801–5. Available from:
 https://linkinghub.elsevier.com/retrieve/pii/S1551741118307757
- 678 32. Elwyn G, Laitner S, Coulter A, Walker E, Watson P, Thomson R. Implementing shared

- decision making in the NHS. BMJ. 2010 Oct 14;341(oct14 2):c5146–c5146. Available from:
- 680 http://www.bmj.com/content/341/bmj.c5146.abstract
- 681 33. Simmons M, Hetrick S, Jorm A. Shared Decision-Making: Benefits, Barriers and Current
- 682 Opportunities for Application. Australas Psychiatry. 2010 Oct 1;18(5):394–7. Available from:
- 683 http://journals.sagepub.com/doi/10.3109/10398562.2010.499944
- 684 34. O'Connor AM, Rostom A, Fiset V, Tetroe J, Entwistle V, Llewellyn-Thomas H, et al. Decision
 685 aids for patients facing health treatment or screening decisions: systematic review. BMJ. 1999
 686 Sep 18;319(7212):731–4. Available from: https://pubmed.ncbi.nlm.nih.gov/10487995
- 687 35. Durand MA, Carpenter L, Dolan H, Bravo P, Mann M, Bunn F, et al. Do Interventions
- 688 Designed to Support Shared Decision-Making Reduce Health Inequalities? A Systematic
- Review and Meta-Analysis. Malaga G, editor. PLoS One. 2014 Apr 15;9(4):e94670. Available
 from: https://doi.org/10.1371/journal.pone.0094670
- Sutton RT, Pincock D, Baumgart DC, Sadowski DC, Fedorak RN, Kroeker KI. An overview of
 clinical decision support systems: benefits, risks, and strategies for success. npj Digit Med.
 2020 Dec 6;3(1):17. Available from: http://dx.doi.org/10.1038/s41746-020-0221-y
- Tamblyn R, Eguale T, Buckeridge DL, Huang A, Hanley J, Reidel K, et al. The effectivenessof a new generation of computerized drug alerts in reducing the risk of injury from drug side
- effects: a cluster randomized trial. J Am Med Informatics Assoc. 2012 Jul 1;19(4):635–43.
- 697 Available from: https://academic.oup.com/jamia/article-lookup/doi/10.1136/amiajnl-2011698 000609
- Kouladjian O'Donnell L, Gnjidic D, Sawan M, Reeve E, Kelly PJ, Chen TF, et al. Impact of
 the Goal-directed Medication Review Electronic Decision Support System on Drug Burden
 Index: A cluster-randomised clinical trial in primary care. Br J Clin Pharmacol. 2021 Mar
 2;87(3):1499–511. Available from: https://onlinelibrary.wiley.com/doi/10.1111/bcp.14557
- 39. Rieckert A, Reeves D, Altiner A, Drewelow E, Esmail A, Flamm M, et al. Use of an electronic

- decision support tool to reduce polypharmacy in elderly people with chronic diseases: cluster
- randomised controlled trial. BMJ. 2020 Jun 18;369:m1822. Available from:
- 706 https://www.bmj.com/lookup/doi/10.1136/bmj.m1822
- 40. Damoiseaux-Volman BA, van der Velde N, Ruige SG, Romijn JA, Abu-Hanna A, Medlock S.
- 708 Effect of Interventions With a Clinical Decision Support System for Hospitalized Older
- 709 Patients: Systematic Review Mapping Implementation and Design Factors. JMIR Med
- 710 Informatics. 2021 Jul 16;9(7):e28023. Available from:
- 711 https://medinform.jmir.org/2021/7/e28023
- 712 41. Turner AM, Osterhage K, Hartzler A, Joe J, Lin L, Kanagat N, et al. Use of Patient Portals for
- 713 Personal Health Information Management: The Older Adult Perspective. AMIA . Annu Symp
- 714 proceedings AMIA Symp. 2015;2015:1234–41. Available from:
- 715 http://www.ncbi.nlm.nih.gov/pubmed/26958263
- 716 42. Carini E, Villani L, Pezzullo AM, Gentili A, Barbara A, Ricciardi W, et al. The Impact of
- 717 Digital Patient Portals on Health Outcomes, System Efficiency, and Patient Attitudes: Updated
- 718 Systematic Literature Review. J Med Internet Res. 2021 Sep 8;23(9):e26189. Available from:
- 719 https://www.jmir.org/2021/9/e26189
- 43. Tieu L, Sarkar U, Schillinger D, Ralston JD, Ratanawongsa N, Pasick R, et al. Barriers and
- Facilitators to Online Portal Use Among Patients and Caregivers in a Safety Net Health Care
- 722 System: A Qualitative Study. J Med Internet Res. 2015 Dec 3;17(12):e275. Available from:
- 723 http://www.jmir.org/2015/12/e275/
- 44. Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013
- explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013 Jan
- 726 9;346(jan08 15):e7586–e7586. Available from:
- 727 https://www.bmj.com/lookup/doi/10.1136/bmj.e7586
- 45. Campbell MK, Piaggio G, Elbourne DR, Altman DG. Consort 2010 statement: extension to
- cluster randomised trials. BMJ. 2012 Sep 4;345(sep04 1):e5661–e5661. Available from:

730 https://www.bmj.com/lookup/doi/10.1136/bmj.e5661

- 46. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and evaluating
- complex interventions: the new Medical Research Council guidance. BMJ. 2008 Sep
- 733 29;337(7676):a1655. Available from: http://dx.doi.org/doi:10.1136/bmj.a1655
- 47. van de Loo B, Seppala LJ, van der Velde N, Medlock S, Denkinger M, de Groot LC, et al.
- 735 Development of the ADF ICE_IT Models for Predicting Falls and Recurrent Falls in
- 736 Community-Dwelling Older Adults: Pooled Analyses of European Cohorts With Special
- 737 Attention to Medication. Lipsitz LA, editor. Journals Gerontol Ser A. 2022 Jul 5;77(7):1446–
- 738 54. Available from: https://academic.oup.com/biomedgerontology/advance-
- 739 article/doi/10.1093/gerona/glac080/6563350
- 48. Ploegmakers KJ, Medlock S, Linn AJ, Lin Y, Seppälä LJ, Petrovic M, et al. Barriers and
- facilitators in using a Clinical Decision Support System for fall risk management for older
 people: a European survey. Eur Geriatr Med. 2022 Apr 15;13(2):395–405. Available from:
 https://doi.org/10.1007/s41999-021-00599-w
- 49. Hill KD, Moore KJ, Dorevitch MI, Day LM. Effectiveness of Falls Clinics: An Evaluation of

745 Outcomes and Client Adherence to Recommended Interventions. J Am Geriatr Soc. 2008

- 746 Apr;56(4):600–8. Available from: https://onlinelibrary.wiley.com/doi/10.1111/j.1532-
- 747 5415.2007.01626.x
- 50. Trzepacz PT, Hochstetler H, Wang S, Walker B, Saykin AJ. Relationship between the
- 749 Montreal Cognitive Assessment and Mini-mental State Examination for assessment of mild
- cognitive impairment in older adults. BMC Geriatr. 2015 Dec 7;15(1):107. Available from:
- 751 http://dx.doi.org/10.1186/s12877-015-0103-3
- 752 51. Federation of Medical Specialists. Effect of medication on fall risk in older adults [In Dutch:
- Effect medicijnen op valrisico ouderen] [Internet]. 2017 [cited 2022 Jul 6]. Available from:
- 754 https://richtlijnendatabase.nl/richtlijn/preventie_van_valincidenten_bij_ouderen/effect_medicij
- 755 nen_op_valrisico_ouderen.html

- 52. Medlock S, Opondo D, Eslami S, Askari M, Wierenga P, de Rooij SE, et al. LERM (Logical
- 757 Elements Rule Method): A method for assessing and formalizing clinical rules for decision
- support. Int J Med Inform. 2011 Apr;80(4):286–95. Available from:
- 759 http://dx.doi.org/10.1016/j.ijmedinf.2011.01.014
- 760 53. Brandes K, Linn AJ, Butow PN, van Weert JCM. The characteristics and effectiveness of
- 761 Question Prompt List interventions in oncology: a systematic review of the literature.
- 762 Psychooncology. 2015 Mar;24(3):245–52. Available from:
- 763 https://onlinelibrary.wiley.com/doi/abs/10.1002/pon.3637
- 54. Schwenk M, Lauenroth A, Stock C, Moreno RR, Oster P, McHugh G, et al. Definitions and
- methods of measuring and reporting on injurious falls in randomised controlled fall prevention
- trials: a systematic review. BMC Med Res Methodol. 2012 Dec 17;12(1):50. Available from:
- 767 http://www.biomedcentral.com/1471-2288/12/50
- 55. Lamb SE, JÃ, rstad-Stein EC, Hauer K, Becker C. Development of a Common Outcome Data
- 769 Set for Fall Injury Prevention Trials: The Prevention of Falls Network Europe Consensus. J
- Am Geriatr Soc. 2005 Sep;53(9):1618–22. Available from:
- 771 https://onlinelibrary.wiley.com/doi/10.1111/j.1532-5415.2005.53455.x
- 56. M. Versteegh M, M. Vermeulen K, M. A. A. Evers S, de Wit GA, Prenger R, A. Stolk E.
- 773 Dutch Tariff for the Five-Level Version of EQ-5D. Value Heal. 2016 Jun;19(4):343–52.
- 774 Available from: http://dx.doi.org/10.1016/j.jval.2016.01.003
- 57. Santoso AMM, Lutomski JE, Hofman CS, Metzelthin SF, Blom JW, van der Wees PJ, et al.
- 776 Development of a Patient-Reported Outcome Measure for Geriatric Care: The Older Persons
- and Informal Caregivers Survey Short Form. Value Heal. 2018 Oct;21(10):1198–204.
- 778 Available from: http://dx.doi.org/10.1016/j.jval.2018.02.011
- 58. Group TE. EuroQol a new facility for the measurement of health-related quality of life.
- 780 Health Policy (New York). 1990 Dec;16(3):199–208. Available from:
- 781 https://linkinghub.elsevier.com/retrieve/pii/0168851090904219

782	59.	Bouwmans C, Hakkaart-van Roijen L, Koopmanschap M, Krol M, Severens H BW. Manual
783		iMTA medical cost ques- tionnaire (iMCQ) [in Dutch: Handleiding iMTA medical cost ques-
784		tionnaire (iMCQ)]. 2013.
785	60.	Bouwmans C, Krol M, Severens H, Koopmanschap M, Brouwer W, Hakkaart-van Roijen L.
786		The iMTA Productivity Cost Questionnaire: A Standardized Instrument for Measuring and
787		Valuing Health-Related Productivity Losses. Value Health. 2015 Sep;18(6):753-8. Available
788		from: http://dx.doi.org/10.1016/j.jval.2015.05.009
789	61.	Davis FD. Technology Acceptance Model: TAM. Al-Suqri, MN, Al-Aufi, AS Inf Seek Behav
790		Technol Adopt S. 1989;205–19.
791	62.	Bol N, van Weert JCM, de Haes HCJM, Loos EF, de Heer S, Sikkel D, et al. Using Cognitive
792		and Affective Illustrations to Enhance Older Adults' Website Satisfaction and Recall of Online
793		Cancer-Related Information. Health Commun. 2014 Aug 9;29(7):678-88. Available from:
794		http://www.tandfonline.com/doi/abs/10.1080/10410236.2013.771560
795	63.	Bomhof-Roordink H, Stiggelbout AM, Gärtner FR, Portielje JEA, de Kroon CD, Peeters
796		KCMJ, et al. Patient and physician shared decision-making behaviors in oncology: Evidence on
797		adequate measurement properties of the iSHARE questionnaires. Patient Educ Couns. 2022
798		May;105(5):1089–100. Available from: https://doi.org/10.1016/j.pec.2021.08.034
799	64.	Pel-Littel RE, Buurman BM, van de Pol MH, Yilmaz NG, Tulner LR, Minkman MM, et al.
800		Measuring triadic decision making in older patients with multiple chronic conditions: Observer
801		OPTIONMCC. Patient Educ Couns. 2019 Nov;102(11):1969–76. Available from:
802		https://www.sciencedirect.com/science/article/pii/S0738399119302538
803	65.	Bennett C, Graham ID, Kristjansson E, Kearing SA, Clay KF, O'Connor AM. Validation of a
804		Preparation for Decision Making scale. Patient Educ Couns. 2010 Jan;78(1):130–3. Available
805		from: https://www.sciencedirect.com/science/article/pii/S0738399109002328
806	66.	O'Connor AM. Validation of a Decisional Conflict Scale. Med Decis Mak. 1995 Feb

medRxiv preprint doi: https://doi.org/10.1101/2023.07.19.23292866; this version posted July 23, 2023. The copyright holder for this pr (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpet It is made available under a CC-BY 4.0 International license.			
807		2;15(1):25–30. Available from:	
808		http://journals.sagepub.com/doi/10.1177/0272989X9501500105	
809	67.	O'Connor AM. User Manual – Decisional Conflict Scale.	
810		Https://DecisionaidOhriCa/Eval_DcsHtml. 1993;1-16.	
811	68.	Jansen J, van Weert J, van der Meulen N, van Dulmen S, Heeren T, Bensing J. Recall in Older	
812		Cancer Patients: Measuring Memory for Medical Information. Gerontologist. 2008 Apr	
813		1;48(2):149-57. Available from: https://doi.org/10.1093/geront/48.2.149	
814	69.	Austin PC. A Tutorial on Multilevel Survival Analysis: Methods, Models and Applications. Int	
815		Stat Rev. 2017 Aug;85(2):185–203. Available from:	
816		https://onlinelibrary.wiley.com/doi/10.1111/insr.12214	
817	70.	Twisk J, Bosman L, Hoekstra T, Rijnhart J, Welten M, Heymans M. Different ways to estimate	
818		treatment effects in randomised controlled trials. Contemp Clin Trials Commun. 2018	
819		Jun;10(March):80–5. Available from:	
820		https://linkinghub.elsevier.com/retrieve/pii/S2451865417301849	
821	71.	Adams G, Gulliford MC, Ukoumunne OC, Eldridge S, Chinn S, Campbell MJ. Patterns of	
822		intra-cluster correlation from primary care research to inform study design and analysis. J Clin	
823		Epidemiol. 2004 Aug;57(8):785–94. Available from:	

- 824 https://linkinghub.elsevier.com/retrieve/pii/S0895435604000459
- 72. Shay LA, Lafata JE. Where Is the Evidence? A Systematic Review of Shared Decision Making 825
- 826 and Patient Outcomes. Med Decis Mak. 2015 Jan 28;35(1):114-31. Available from:
- http://journals.sagepub.com/doi/10.1177/0272989X14551638 827
- 73. Boyé N. Effectiveness of medication withdrawal in older fallers : results from the Improving 828 829 Medication Prescribing to reduce Risk Of FALLs (IMPROveFALL) trial. 2016;142-6.
- 74. Bhasin S, Gill TM, Reuben DB, Latham NK, Ganz DA, Greene EJ, et al. A Randomized Trial 830
- of a Multifactorial Strategy to Prevent Serious Fall Injuries. N Engl J Med. 2020 Jul 831

832 9;383(2):129–40. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2002183

Items from the World Health Organization Trial Registration Data Set

1. Primary Registry and Trial Identifying Number

Name of Primary Registry, and the unique ID number assigned by the Primary Registry to this trial.

Name of Primary Registry: ClinicalTrials.gov

ID number assigned by the Primary Registry to this trial: NCT05449470

2. Date of Registration in Primary Registry

Date when trial was officially registered in the Primary Registry.

7-7-2022

3. Secondary Identifying Numbers

Other identifiers besides the Trial Identifying Number allocated by the Primary Registry, if any. These include:

- The Universal Trial Number (UTN)
- Identifiers assigned by the sponsor (record Sponsor name and Sponsor-issued trial number (e.g. protocol number))
- Other trial registration numbers issued by other Registries (both Primary and Partner Registries in the WHO Registry Network, and other registries)
- Identifiers issued by funding bodies, collaborative research groups, regulatory authorities, ethics committees / institutional review boards, etc.

All secondary identifiers will have 2 elements: an identifier for the issuing authority (e.g. NCT, ISRCTN, ACTRN) plus a number.

There is no limit to the number of secondary identifiers that can be provided.

Identifier as given by the Dutch Central Committee on Research Involving Human Subjects (<u>https://english.ccmo.nl/</u>): NL76386.018.21

Identifier as given by the Medical Ethics review board of the Amsterdam University Medical Centres: METC AMC 2021_061

4. Source(s) of Monetary or Material Support

Major source(s) of monetary or material support for the trial (e.g. funding agency, foundation, company, institution).

The ADFICE_IT study is supported by funding from the Netherlands Organization for Health Research and Development (ZonMw, Grant 848017004), The Hague and the Amsterdams Universiteitsfonds: Gepersonaliseerde Medicatieaanpassing bij Oudere Vallers.

5. Primary Sponsor

The individual, organization, group or other legal entity which takes responsibility for initiating, managing and/or financing a study. The Primary Sponsor is responsible for ensuring that the trial is properly registered. The Primary Sponsor may or may not be the main funder.

The sponsor of this study is the Amsterdam UMC.

6. Secondary Sponsor(s)

Additional individuals, organizations or other legal persons, if any, that have agreed with the primary sponsor to take on responsibilities of sponsorship.

A secondary sponsor may have agreed to:

- take on all the responsibilities of sponsorship jointly with the primary sponsor; or
- form a group with the Primary Sponsor in which the responsibilities of sponsorship are allocated among the members of the group; or
- act as the Primary Sponsor's legal representative in relation to some or all of the trial sites.

There are no secondary sponsors.

7. Contact for Public Queries

Email address, telephone number and postal address of the contact who will respond to general queries, including information about current recruitment status.

"Note: The information provided in here is functional and not personal, it is recommended to provide institutional and not personal information. By providing this information the registrant consents that the information provided can or may be published on a public website. Once provided the information cannot be redacted or anonymized as a result of new privacy legislation such as the European General Data Protection Regulation (GDPR)".

Contact: N. van der Velde

Telephone number: +3120 566 9111

Address: Amsterdam UMC location University of Amsterdam, Internal Medicine, Section of Geriatric Medicine, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands

8. Contact for Scientific Queries

There must be clearly assigned responsibility for scientific leadership to a named Principal Investigator. The PI may delegate responsibility for dealing with scientific enquiries to a scientific contact for the trial. This scientific contact will be listed in addition to the PI.

"Note: The information provided in here is functional and not personal, it is recommended to provide institutional and not personal information. By providing this information the registrant consents that the information provided can or may be published on a public website. Once provided the information cannot be redacted or anonymized as a result of new privacy legislation such as the European General Data Protection Regulation (GDPR)".

The contact for scientific queries must include:

• Name and title, email address, telephone number, postal address and affiliation of the Principal Investigator, and;

• Email address, telephone number, postal address and affiliation of the contact for scientific queries about the trial (if applicable). The details for the scientific contact may be generic (that is, there does not need to be a named individual): e.g. a generic email address for research team members qualified to answer scientific queries.

Contact: Prof. Dr. Nathalie van der Velde

Telephone number: +3120 566 9111

Address: Amsterdam UMC location University of Amsterdam, Internal Medicine, Section of Geriatric Medicine, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands

9. **Public Title**

Title intended for the lay public in easily understood language.

A Clinical Decision Support System and Patient Portal for Preventing Medication-related Falls in Older Patients

10. Scientific Title

Scientific title of the study as it appears in the protocol submitted for funding and ethical review. Include trial acronym if available.

A Clinical Decision Support System and Patient Portal for Preventing Medication-related Falls in Older Patients (ADFICE_IT)

11. Countries of Recruitment

The countries from which participants will be, are intended to be, or have been recruited at the time of registration.

Netherlands

12. Health Condition(s) or Problem(s) Studied

Primary health condition(s) or problem(s) studied (e.g., depression, breast cancer, medication error).

If the study is conducted in healthy human volunteers belonging to the target population of the intervention (e.g. preventive or screening interventions), enter the particular health condition(s) or problem(s) being prevented.

Prevention of medication-related injurious falls.

13. Intervention(s)

For each arm of the trial record a brief intervention name plus an intervention description.

<u>Intervention Name</u>: For drugs use generic name; for other types of interventions provide a brief descriptive name.

• For investigational new drugs that do not yet have a generic name, a chemical name, company code or serial number may be used on a temporary basis. As

soon as the generic name has been established, update the associated registered records accordingly.

• For non-drug intervention types, provide an intervention name with sufficient detail so that it can be distinguished from other similar interventions.

<u>Intervention Description</u>: Must be sufficiently detailed for it to be possible to distinguish between the arms of a study (e.g. comparison of different dosages of drug) and/or among similar interventions (e.g. comparison of multiple implantable cardiac defibrillators). For example, interventions involving drugs may include dosage form, dosage, frequency and duration.

If the intervention is one or more drugs then use the International Non-Proprietary Name for each drug if possible (not brand/trade names). For an unregistered drug, the generic name, chemical name, or company serial number is acceptable.

If the intervention consists of several separate treatments, list them all in one line separated by commas (e.g. "low-fat diet, exercise").

For controlled trials, the identity of the control arm should be clear. The control intervention(s) is/are the interventions against which the study intervention is evaluated (e.g. placebo, no treatment, active control). If an active control is used, be sure to enter in the name(s) of that intervention, or enter "placebo" or "no treatment" as applicable. For each intervention, describe other intervention details as applicable (dose, duration, mode of administration, etc).

Intervention Name: ADFICE_IT CDSS and Patient Portal for optimizing deprescribing of fall-risk-increasing drugs

In this study we will evaluate the effect of an intervention comprised of the combined use of a clinical decision support system and a patient portal for optimizing the deprescribing of FRIDs in older fallers. Patients in the control arm will receive care-as-usual.

14. Key Inclusion and Exclusion Criteria

Inclusion and exclusion criteria for participant selection, including age and sex. Other selection criteria may relate to clinical diagnosis and co-morbid conditions; exclusion criteria are often used to ensure patient safety.

If the study is conducted in healthy human volunteers not belonging to the target population (e.g. a preliminary safety study), enter "healthy human volunteer".

Patients meeting the following criteria are eligible for inclusion:

- Aged 65 years and older;
- History of at least one fall in the past year;

medRxiv preprint doi: https://doi.org/10.1101/2023.07.19.23292866; this version posted July 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

- A Mini-Mental State Examination (MMSE) score of 21 points or higher or equivalently a Montreal Cognitive Assessment (MOCA) Dutch score of 16 points or higher (50);
- Use of at least one FRID (as defined by the Dutch Federation of Medical Specialists (51));
- Sufficient command of the Dutch language in speech and writing; and
- Willingness to sign informed consent.

Potential subjects will be excluded if they:

- Already participate in another (intervention) study;
- Have a life expectancy of less than one year; or
- Suffer from severe mobility impairment (i.e. bedridden, e.g. inability to walk short distances

with assistance of a walking aid).

15. Study Type

Study type consists of:

- Type of study (interventional or observational)
- Study design including:
 - Method of allocation (randomized/non-randomized)
 - Masking (is masking used and, if so, who is masked)
 - Assignment (single arm, parallel, crossover or factorial)
 - Purpose
- Phase (if applicable)

For randomized trials: the allocation concealment mechanism and sequence generation will be documented.

This study is a a multicenter, cluster-randomized controlled trial. Masking will not be used. Assignment will be at random and at the level of the cluster.

16. Date of First Enrollment

Anticipated or actual date of enrolment of the first participant.

The first patient was enrolled on 7 July 2022.

17. Sample Size

Sample Size consists of:

- Number of participants that the trial plans to enrol in total.
- Number of participants that the trial has enrolled.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.19.23292866; this version posted July 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

The trial plans on enrolling 856 participants. A total of 8 participants have currently been enrolled at the point of this submission.

18. Recruitment Status

Recruitment status of this trial:

- Pending: participants are not yet being recruited or enrolled at any site
- Recruiting: participants are currently being recruited and enrolled
- o Suspended: there is a temporary halt in recruitment and enrolment
- Complete: participants are no longer being recruited or enrolled
- o Other

The status of this trial is: recruiting (participants are currently being recruited and enrolled).

19. Primary Outcome(s)

Outcomes are events, variables, or experiences that are measured because it is believed that they may be influenced by the intervention.

The Primary Outcome should be the outcome used in sample size calculations, or the main outcome(s) used to determine the effects of the intervention(s). Most trials should have only one primary outcome.

For each primary outcome provide:

- The name of the outcome (do not use abbreviations)
- The metric or method of measurement used (be as specific as possible)
- The timepoint(s) of primary interest

Example: Outcome Name: Depression Metric/method of measurement: Beck Depression Score Timepoint: 18 weeks following end of treatment

The primary outcome is time to first injurious fall. Injurious falls will be recorded prospectively over a period of one year, using weekly fall calendars.

20. Key Secondary Outcomes

Secondary outcomes are outcomes which are of secondary interest or that are measured at timepoints of secondary interest. A secondary outcome may involve the same event, variable, or experience as the primary outcome, but measured at timepoints other than those of primary interest.

As for primary outcomes, for each secondary outcome provide:

- The name of the outcome (do not use abbreviations)
- The metric or method of measurement used (be as specific as possible)
- The timepoint(s) of interest

Number of injurious falls [Time Frame: 12 months]

This concerns the total number of injuirous falls over the course of 12 months. An injurious fall is defined as a fall resulting in wounds, bruises, sprains, cuts, medically

recorded fractures, head or internal injury, requiring medical/health professional examination, accident and emergency treatment, or inpatient treatment.

Total number of falls [Time Frame: 12 months]

Total number of any fall (I.e. a fall that results in no injuries, or minor, moderate, or severe injuries)

Time to first fall resulting in any injuries [Time Frame: 12 months]

I.e. a fall that results in minor, moderate, or severe injuries

Total number of falls resulting in any injuries [Time Frame: 12 months]

I.e. a fall that results in minor, moderate, or severe injuries

Time to first non-injurious fall [Time Frame: 12 months]

I.e. a fall that results in no injuries

EuroQol-5D-5L (EQ-5D-5L) [Time Frame: at baseline, 3 months, 6 months, and 12 months]

The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension in the EQ-5D-5L has five response levels: no problems (Level 1); slight; moderate; severe; and extreme problems (Level 5). Furthermore, it includes a visual analogue scale (EQ-VAS) which provides a single global rating of self-perceived health and is scored on a 0 (worst health imaginable) to 100 (best health imaginable) scale.

The Older Persons and Informal Caregivers Minimum Data Set-Short Form (TOPICS-SF) [Time Frame: at baseline and 12 months]

Data as measured by the The Older Persons and Informal Caregivers Minimum Data Set-Short Form (TOPICS-SF) will be analysed based on the preference-weighted score, ranging from 1.90 to 9.78, with higher scores reflecting a better health status, as perceived by the respondent. The TOPICS - Short Form 2017 including Casemix forms were developed in collaboration with the Nederlandse Vereniging voor Klinische Geriatrie (NvKG - Dutch Association for Clinical Geriatrics) to use as a Patient Reported Outcome Measure (PROM) in the Dutch outpatient and clinical daily practice. iMTA Productivity Cost Questionnaire (iPCQ) [Time Frame: at baseline, 3 months, 6 months, and 12 months]

Direct and indirect costs related to the intervention and care as usual will be assessed using the iMTA Productivity Cost Questionnaire (iPCQ).

iMTA Medical Consumption Questionnaire (iMCQ) [Time Frame: at baseline, 3 months, 6 months, and 12 months]

The iMTA Medical Consumption Questionnaire (iMCQ) is an instrument for measuring medical consumption. The iMCQ includes questions related to frequently occurring contacts with health care providers.

Feasibility assessed by number of CDSS and patient portal use [Time Frame: 12 months]

To assess the feasibility of the intervention, the investigators will use data logged by the CDSS and patient portal to understand how (often) the CDSS and patient portal are used

Percentage of physicians attending the CDSS training via a questionnaire [Time Frame: 12 months]

To assess the feasibility of the intervention, the investigators will look at the percentage of physicians who attended the CDSS training. More specifically, this will be measured by asking physicians whether they attended the CDSS training online, offline or not at all as part of the CDSS user satisfaction questionnaire.

Correlation of percentage of physicians attending the CDSS training and CDSS user satisfaction [Time Frame: 12 months]

The correlation between the proportion of a department's staff members who did/did not participate in the CDSS training and user satisfaction regarding the CDSS will be assessed.

CDSS user satisfaction [Time Frame: 12 months]

To assess the feasibility of the intervention, the investigators will study the satisfaction regarding the CDSS (i.e. physician evaluations of the CDSS). Agreement

with satisfaction statements will be scored on a 7-point Likert scale (1= totally disagree; 7 = totally agree).

Technology Acceptance Model (TAM) [Time Frame: at baseline]

The Technology Acceptance Model (TAM) is designed to measure the adoption of a new technology/system based on user attitudes. 6 items aim to measure Perceived Usefulness on a 7-point Likert scale (1=totally disagree; 7 = totally agree), and 6 items aim to measure Perceived Ease of Use on a 7-point Likert scale (1=totally disagree; 7 = totally agree). Intention to use is measured through 1 item on a 7-point Likert scale (1=totally disagree; 7 = totally disagree; 7 = totally disagree; 7 = totally disagree; 7 = totally agree).

Website Satisfaction Scale (WSS) [Time Frame: at 3 months]

The Website Satisfaction Scale (WSS) measures satisfaction with comprehensibility, satisfaction with attractiveness, and satisfaction with emotional support through 12 items, for each sub scale using a 7-point Likert response scale, ranging from 1 'totally disagree' to 7 'totally agree'.

Observer OPTION Multiple Chronic Conditions (OPTION-MCC) [Time Frame: 12 months]

Videotaped consultations will be coded on triadic decision making in older patients with multiple chronic conditions by using the Observer OPTION Multiple Chronic Conditions (OPTION-MCC) coding scheme. Six types of physicians', patients', and caregivers' behaviors are coded. Physicians' behavior is coded on a 5-point scale (0= The behavior is not observed; 4=The behavior is executed to a very high standard), patients' behavior is coded on a 3-point scale (0=No or minimal participation, e.g. only yes or no; 2=Active participation, answers questions and asks questions, brings in own ideas and shares perceptions), and informal caregivers' behavior is coded on a 3-point scale (0=No or minimal participation, e.g. only yes or no; 2=Active participation, answers questions, brings in own ideas and shares perceptions)

Rate of adherence to new medication plan using pharmacy records [Time Frame: 12 months]

To assess adherence to the medication advice, the investigators will compare a patient's new medication advice with their pharmacy records to determine whether a patient adheres to the new medication advice or whether they (eventually) change back to their old medication

Number of falls calendar entries [Time Frame: 12 months]

To assess adherence to the medication advice, the investigators will compare the new medication advice with falls calender entries on medication use to determine whether a patient adheres to the new medication advice or whether they (eventually) change back to their old medication

iSHARE [Time Frame: 12 months]

To evaluate how the intervention facilitates SDM, the investigators will use the iSHAREpatient and iSHAREphysician questionnaires. The iSHAREphysician consists of 16 items scored on a 6-point Likert scale (1= did not do this at all; 6 = completely did this). The iSHAREpatient consists of 16 items scored on a 6-point Likert scale (1= did not do this at all; 6 = completely did this). Dimension scores (range, 0-5) and a total score (the sum of the dimension scores; range, 0-30) for both iSHARE questionnaires will be calculated. The investigators will then apply a linear transformation to obtain a 0 to 100 total score ((score/30)*100). Higher dimension and total scores indicate higher levels of SDM.

Decisional Conflict Scale (DCS; low literacy scale) [Time Frame: at baseline]

To evaluate how the intervention facilitates SDM, the investigators will use the Decisional Conflict Scale (DCS; low literacy scale). This scale consists of 10 questions, scored on 3 response categories (yes, do not know, no).

Preparation for Decision-making scale (PrepDM) [Time Frame: at baseline]

To evaluate how the intervention facilitates SDM, the investigators will use the Preparation for Decision-making scale (PrepDM). This scale consists of 10 items, scored on a 5-point Likert scale (1= not at all; 5 = a great deal)

Netherlands Patient Information Recall Questionnaire (NPIRQ) [Time Frame: 12 months]

To evaluate how the intervention facilitates SDM, the investigators will use the Netherlands Patient Information Recall Questionnaire (NPIRQ). This questionnaire consists of open questions.

21. Ethics Review

The ethics review process information of the trial record in the primary register database. It consists of:

- Status (possible values: Not approved, Approved, Not Available)
- Date of approval
- Name and contact details of Ethics committee(s)

Our study protocol was reviewed and approved by the Medical Ethics review board of the Amsterdam University Medical Centres. The date of approval was: 28/09/2021. The committee can be contacted by mail: mecamc@amsterdamumc.nl

22. Completion date

Date of study completion: The date on which the final data for a clinical study were collected (commonly referred to as, "last subject, last visit").

N/A: data collection is still ongoing.

23. Summary Results

It consists of:

• Date of posting of results summaries

- Date of the first journal publication of results
- URL hyperlink(s) related to results and publications
- Baseline Characteristics: Data collected at the beginning of a clinical study for all participants and for each arm or comparison group. These data include demographics, such as age and sex, and study-specific measures.
- Participant flow: Information to document the progress and numbers of research participants through each stage of a study in a flow diagram or tabular format.
- Adverse events: An unfavorable change in the health of a participant, including abnormal laboratory findings, and all serious adverse events and deaths that happen during a clinical study or within a certain time period after the study has ended. This change may or may not be caused by the intervention being studied.
- Outcome measures: A table of data for each primary and secondary outcome measure and their respective measurement of precision (eg a 95% confidence interval) by arm (that is, initial assignment of participants to arms or groups) or comparison group (that is, analysis groups), including the result(s) of scientifically appropriate statistical analyses that were performed on the outcome measure data, if any.
- URL link to protocol file(s) with version and date
- Brief summary

Data collection is still ongoing. Results of this study have not yet been published or submitted to any journal.

24. IPD sharing statement

Statement regarding the intended sharing of deidentified individual clinical trial participant-level data (IPD). Should indicate whether or not IPD will be shared, what IPD will be shared, when, by what mechanism, with whom and for what types of analyses. It consists of:

- Plan to share IPD (Yes, No)
- Plan description

We plan on sharing the IPD after the trial has been completed, all research data will be made available for other researchers for replication purposes and for original research questions. To obtain data, researchers will need to submit an analysis proposal, which will be evaluated by the steering group.



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	ltemN o	Description	Page
Administrative infor	mation		
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
ned Pair proponistina by Ordi.org/10.11 (which was not certified by peer revie It is	012ca3.07.19.2 w) is the author, s made available	232 Datase this experiposed 2005, 703 Tel covyretainmer for his reprint r/funder, who has granted medRxiv a license to display the preprint in perpetuity. le under a CC-BY 4.0 International license. Yet registered, name of intended registry	3
	2b	All items from the World Health Organization Trial Registration Data Set	32
Protocol version	3	Date and version identifier	3
Funding	4	Sources and types of financial, material, and other support	Funding, page 21
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	Authors' contributions, page 21
	5b	Name and contact information for the trial sponsor	3
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	Funding, page 21
	5d	Composition, roles, and responsibilities of the coordinating centre, steering	N/A

committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)

1

Introduction

Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	Background, page 3	
	6b	Explanation for choice of comparators	Comparator, page 10	
Objectives	7	Specific objectives or hypotheses	Background, page 6	
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority,	Study design and settings, page 7	
medRxiv preprint doi: https://doi.org/10.11 (which was not certified by peer revie It is	01/2023.07.19. (w) is the author (s made available)	23 244 Michaelo posted 049 23, 2023. The copyright Adde for this preprint /funder, who has granted medRxiv a license to display the preprint in perpetuity. e under a CC-BY 4.0 International license .		
Methods: Participan	nts, inte	rventions, and outcomes		
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	Eligibility criteria, page 7	
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	Eligibility criteria, page 7	
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	Intervention, page 8	
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	N/A	
	11c	Strategies to improve adherence to	N/A	

intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)

11d Relevant concomitant care and N/A interventions that are permitted or prohibited during the trial

Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	Data collection, page 11
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for	Data collection, page 11
medRxiv preprint doi: https://doi.org/10.1 (which was not certified by peer revious lt It	101/2023.07.19 ew) is the authc is made availab	23292666; this version posted July 23; 2023: The copyright holder for this preprint r/funder, who has granted medRxiv a license to display the preprint in perpetuity. le upenatic diagram is highly recommended (see Figure)	
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	Sample size, page 16
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	N/A
Methods: Assignme	ent of in	terventions (for controlled trials)	
Allocation:			
Sequence 16a Me generation sec ran fac pre def blo sep to f		Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	Randomization and blinding, page 8

Allocation concealment mechanism 16b

Mechanism of implementing the N/A allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned

Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	Randomization and blinding, page 8		
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	Randomization and blinding, page 8		
17b		If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	N/A		
Martin perfector Diatra Golde (which was not certified by peer revie	w) is the author	//under, who has granted medRxiv a license to display the preprint in perpetuity. e under a CC-BY 4.0 International license .			
Data collection methods	s made availabl 18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol			
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	N/A		
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	Data management, page 14		

Statistical methods 20a

Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol

20b Methods for any additional analyses Per protocol analysis, page 16 (eg, subgroup and adjusted analyses)

Statistical analysis, page 15

4

	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	Per protocol analysis, page 16
Methods: Monitoring	9		
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the	Monitoring, page 17
medRxiv preprint doi: https://doi.org/10.11 (which was not certified by peer revie It is	01/2023.07.19.2 w) is the author/ made available	its charter can be found, if not in the 3292866: this version posted July 23, 2023. The copyright holder for this preprint funde Owo Gas gramed Ged River all conserve display the predim a begreful of under a CC-BY 4.0 International license. why a DMC is not needed	
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	N/A
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	Harms, page 17
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	N/A
Ethics and dissemin	ation		
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	Ethics approval and consent to participate, page 20
Protocol	25	Plans for communicating important	N/A

 amendments
 protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)
 Consent or assent
 26a
 Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)

	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	Data management, page 14
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	Competing interests, page 20
which was not certified by peer revie It is	012093.07.19. w) is the author s made available	23 Statement polewhos, will have ignore santo reprint /funder, who has granted medRxiv a license to display the preprint in perpetuity. e uther final trian clataset, and disclosure of contractual agreements that limit such access for investigators	Data management, page 14
Ancillary and post- trial care	30	Provisions, if any, for ancillary and post- trial care, and for compensation to those who suffer harm from trial participation	N/A
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	Dissemination policy, page 20
	31b	Authorship eligibility guidelines and any intended use of professional writers	N/A
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	N/A

Appendices

Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	*provided in separate document.
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N/A

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "<u>Attribution-NonCommercial-NoDerivs 3.0 Unported</u>" license.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.19.23292866; this version posted July 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

7

Figure 1. Schedule of study procedures and assessments

		STUDY PERIOD				
		Before and during enrolment		Post-enrolment		
	TIMEPOINT	-t ₁	T₀ (baseline)	t₁ (3 months)	t ₂ (6 months)	t₃(12 months)
	ENROLMENT:					
medRxiv prep (which was	rint doi: https://doi.nrc/10.1101/2023.07.19 not certified by beer tev/ew is the autho It is made availab	23292866; this version posted /funder, who has granted me e under a CC-BY 4.0 Internat	d July 23, 2023. The copyright dRxiv a license to display the onal license .	holder for this preprint preprint preprint in perpetuity.		
	Informed consent	х				
	Cluster allocation	х				
	INTERVENTIONS:					
	Training sessions for physicians in intervention hospitals	х				
	Use of CDSS and patient portal		×			
	ASSESSMENTS:					
	Questionnaires					
	EuroQol-5D-5L (EQ- 5D-5L)		×	×	x	x
	Institute for Medical Technology Assessment Medical Consumption Questionnaire (iMCQ)		x	x	x	x
	Institute for Medical Technology Assessment Productivity Cost Questionnaire (IPCQ)		x	x	x	x
	The Older Persons and Informal Caregivers Survey Short Form (TOPICS-SF)		x			x
	iSHARE patient		×			

	iSHARE physician				
			•		
	Preparation for Decision-making scale (PrepDM)		х		
	Netherlands Patient Information Recall Questionnaire (NPIRQ)			x	
	Decisional Conflict Scale (DCS)		х		
medRxiv prepr	int doi: https://doi.org/foc.h01/20/299/19 not certified by pear review) is the autho	23292866; this version posted	July 23, 2023. The copyright	holder for this preprint	
(which was	(TAM)	e under a CC-BY 4.0 Internat	onal license .	preprint in perpetuity.	
	Website Satisfaction				
	Scale questionnaire (WSS)			×	
	Physicians'				
	Satisfaction with the		+		→
	CDSS				
	Other assessments				
	Attendance training physicians	х			
	Patient portal logs				
	,		+		→
	CDSS logs				
			•		· ·
	Videotaped consultations		+		→
	Falls calendar				
			•		
	Pharmacy records		х		х
	CDSS clinical decisio				

CDSS, clinical decision support system.